Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 8, 2012, Pages 589-595

  Pongprot, Yupada ^a   Sittiwangkul, Rekwan ^a   Charoenkwan, Pimlak ^a   Silvilairat, Suchaya ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

anthracycline; cardiac markers; cardiac toxicity; cardiac troponin T; doxorubicin; natriuretic peptides; NT pro BNP; tissue Doppler imaging

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; DOXORUBICIN; TROPONIN T;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CASE STUDY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; EARLY INTERVENTION; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; EWING SARCOMA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LEFT VENTRICULAR DIASTOLIC FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC FUNCTION; LEUKEMIA; LYMPHOMA; MALE; MITRAL DECELERATION TIME; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PEAK SYSTOLIC VELOCITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CREATINE KINASE, MB FORM; CROSS-SECTIONAL STUDIES; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG MONITORING; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; PEPTIDE FRAGMENTS; STROKE VOLUME; SYSTOLE; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84868632918     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31826faf44     Document Type: Article

References (32)

1. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332: 1738-1743.
2. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:45-47.
3. Shamkar SM, Marina N, Hudson HH, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics. 2008;121:e387-e396.
4. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108:1146-1162.
5. Van Dalen EC, van den Brug M, Caron HN, et al. Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer. 2006;42:3191-3198.
6. Dorup I, levitt G, Sullivan I, et al. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: The role of diastolic function. Heart. 2004;90:1214-1216.
7. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relation with systolic function, symptoms, and pathophysiology. Br Heart J. 1995;73:340-350.
8. Ganame J, Claus P, Eyskens B, et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol. 2007;99:974-977.
9. Karakurt C, Koçak G, Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography. 2008;25:880-887.
10. Baysal T, Koksal Y, Oran B, et al. Cardiac functions evaluated with tissue Doppler imaging in childhood cancers treated with anthracyclines. Pediatr Hematol Oncol. 2010;27:13-23.
11. Babuin L, Jaffe AS. Troponin: The biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173:1191-1202.
12. Herman EH, Lipshultz SE, Rifai N, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998;58:195-197.
13. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999;17:2237-2243.
14. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16:798-804.
15. Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol. 2007;29:309-313.
16. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-1353.
17. Pu DR, Chiong JR, Zhou QC. Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases. Heart Fail Rev. 2010;15:293-304.
18. Fried I, Bar-Oz B, Perles Z, et al. N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. J Pediatr. 2006;149:28-31.
19. Nasser N, Perles Z, Rein AJ, et al. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol. 2006;27:87-90.
20. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction. Clin Chem. 2005;51:1405-1410.
21. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26:1197-1202.
22. Ekstein S, Nir A, Rein AJ, et al. N-terminal-pro-B-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol. 2007;29:440-444.
23. Nir A, Lindinger A, Rauh M, et al. NT-Pro-B-type natriuretic peptide in infants and children: Reference values based on combined data from four studies. Pediatr Cardiol. 2009;30:3-8.
24. Eidem BW, McMahon CJ, Cohen RR, et al. Impact of cardiac growth on Doppler tissue imaging velocities: A study in healthy children. J Am Soc Echocardiogr. 2004;17:212-221.
25. Cui W, Roberson DA. Left ventricular Tei index in children: Comparison of tissue Doppler imaging, pulsed wave Doppler, and M-mode echocardiography normal values. J Am Soc Echocardiogr. 2006;19:1438-1445.
26. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
27. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61-68.
28. Erkus B, Demirtas S, Yarpuzlu AA, et al. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr. 2007;96: 506-509.
29. Aggarwal S, PettersenMD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracyclinetreated children. Pediatr Blood Cancer. 2007;49:812-816.
30. Hongkan W, Soongswang J, Veerakul G, et al. N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients. J Med Assoc Thai. 2009;92: 1450-1547.
31. Dokainish H, Zoghbi WA, Lakkis NM, et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol. 2005;45: 1223-1226.
32. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-153.